Register entry
- Registered sites
- 0
- Active NDC listings
- 12
- Labeller names
- 3
- Live patents
- 13
- Countries
- 0
Catalogue
Drug listings by form and route
1212 active NDC listings: 12 human prescription drug. By marketing category: ANDA 6, NDA 6.
| Dosage form | NDCs |
|---|---|
| injection | 5 |
| injection, powder, lyophilized, for solution | 5 |
| injection, solution | 1 |
| injection, solution, concentrate | 1 |
| Route | NDCs |
|---|---|
| intravenous | 10 |
| intrathecal | 2 |
| Labeller name on the listing | NDCs |
|---|---|
| maia pharmaceuticals, inc. | 10 |
| maia pharmaceuticals | 1 |
| maia pharmaceuticals, inc | 1 |
Exclusivity
Patents and exclusivities
13| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 11110063 | SINCALIDEsincalide | product | Apr 2038 |
| 11318100 | SINCALIDEsincalide | product | Apr 2038 |
| 11737983 | SINCALIDEsincalide | product | Apr 2038 |
| 11903993 | ANGIOMAX RTUbivalirudin | use | May 2039 |
| 11918622 | ANGIOMAX RTUbivalirudin | use | May 2039 |
| 11992514 | ANGIOMAX RTUbivalirudin | product | May 2039 |
| 12472224 | ANGIOMAX RTUbivalirudin | product | May 2039 |
| 11679119 | BORTEZOMIBbortezomib | use | Sept 2042 |
| 11752164 | BORTEZOMIBbortezomib | use | Sept 2042 |
| 12005069 | BORTEZOMIBbortezomib | product | Sept 2042 |
Catalogue
Marketed products
12| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Baclofen (Intrathecal) | baclofen | injection, intrathecal | 70511-122ANDA |
| Baclofen (Intrathecal) | Baclofen | injection, intrathecal | 70511-124ANDA |
| Bivalirudin | Bivalirudin | injection, solution, intravenous | 70511-142NDA |
| Bortezomib | bortezomib | injection, intravenous | 70511-161NDA |
| Bortezomib | bortezomib | injection, intravenous | 70511-162NDA |
| Daptomycin | Daptomycin | injection, powder, lyophilized, for solution, intravenous | 70511-182NDA |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | injection, powder, lyophilized, for solution, intravenous | 70511-111ANDA |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | injection, powder, lyophilized, for solution, intravenous | 70511-112ANDA |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | injection, powder, lyophilized, for solution, intravenous | 70511-113ANDA |
| SODIUM PHENYLACETATE AND SODIUM BENZOATE | sodium phenylacetate and sodium benzoate | injection, solution, concentrate, intravenous | 70511-101ANDA |
| Sincalide | Sincalide | injection, powder, lyophilized, for solution, intravenous | 70511-131NDA |
| Sodium Phenylacetate and Sodium Benzoate | Sodium Phenylacetate and Sodium Benzoate | injection, intravenous | 70511-102NDA |
Compare
Other companies listing levothyroxine sodium anhydrous
- Fresenius Kabi USA, LLC6 sites · 561 NDC
- ONESOURCE SPECIALTY PHARMA LIMITED3 sites · 53 NDC
- Endo USA, Inc.3 sites · 33 NDC
- Fosun Pharma USA Inc.0 sites · 53 NDC
Enquiry
Common questions
- Is MAIA Pharmaceuticals, Inc. FDA approved?
- MAIA Pharmaceuticals, Inc. holds no registered establishment of its own; 12 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does MAIA Pharmaceuticals, Inc. make?
- 12 products are listed under MAIA Pharmaceuticals, Inc. in the openFDA NDC Directory, most often as injection; injection, powder, lyophilized, for solution; injection, solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.